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a b s t r a c t
Microparticles (MP-microparticles) – cell membrane vesicles 0.1–1 mm diameter, released
in response to activation or apoptosis, both in physiological and pathological conditions.
They reveal a wide spectrum of biological activities, express cell surface antigens charac-
teristic for cells of their origin. In this article reviewed quantitative and qualitative
methods for detection of microparticles, presents pre-analytical conditions as an poten-
tial source of variability in the analysis of MP. In conclusion there are several methods
for detection of microparticles but they are not standarized. Methods of microparticles
detection need to be standarized to be clinically relevant.
© 2017 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i
Transfuzjologii. Published by Elsevier Sp. z o.o. All rights reserved.
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journal homepage: www.elsevier.com/locate/achaemMicrovesicles are a heterogeneous group of membrane
vesicles, measuring 0.1–1 mm in diameter that are released
from the cell surface in response to activation or apoptosis
[1–3]. In physiological conditions MVs are formed during cell
maturation and aging, and increased number of circulating
MVs has been associated with many pathological conditions
[2, 4]. MVs are non-nucleated, cell-membrane coated vesi-
cles containing the same surface antigens as their cell of
origin [5].
Our knowledge on the morphology and function of MVs
is still incomplete. This is due to the difficulties in separat-
ing MVs from other types of cells, the inability of most* Corresponding author.
E-mail address: gosiagra@op.pl (M. Gradziuk).
http://dx.doi.org/10.1016/j.achaem.2017.03.003
0001-5814/© 2017 Polskie Towarzystwo Hematologów i Transfuzjologó
z o.o. All rights reserved.techniques to capture particles in a volume range of MVs,
and low availability of costly and time-consuming methods
for the detection of MVs [6]. The majority of studies were
performed on MVs originating from platelets, endothelial
cells, and monocytes [7].
Generation of microvesicles
The formation of MVs is a regulated process, leading to
selective and concentrated release of cell contents to the
surrounding environment. Both the parent cell and a triggerw, Instytut Hematologii i Transfuzjologii. Published by Elsevier Sp.
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Fig. 1 – The formation of microvesicles
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released MVs [8]. Circulating MVs are released to the plasma
from the surface of all types of blood cells: red blood cells,
granulocytes, lymphocytes, monocytes, platelets, endothelial
cells, and tumor cells. The number of MVs in the blood is
the result of a dynamic balance between the release of
apoptotic and activated cells, and their clearance from the
circulation [8–10]. In healthy subjects, the majority of
detected MVs come from platelets, whereas MVs originating
from erythrocytes, leukocytes, and endothelial cells are much
less abundant [7, 11]. Cell membrane is the first structure
involved in the formation of the microvesicles. Under home-
ostatic conditions phospholipids, phosphatidylserine and
phosphatidyloetanolamine, are arranged on the inner (cyto-
plasmic) layer of the membrane while phosphatidylcholine
and sphingomyelin are localized in the outer layer. The
asymmetry is a key factor for maintaining cell homeostasis
and is regulated by an enzyme complex: flippase, floppase
and scramblase. Flippase is responsible for keeping the
phosphatidylserine and phosphatidyloetanolamine on the
inner side of the membrane, while floppase keeps phosphati-
dylcholine and sphingomyelin on the outer side. Scramblase,
responsible for the transport of phospholipids between theTable I – The characteristics of microvesicles











9. Present in physiological conditions Incrtwo monolayers of the cell membrane, is inactive in the
steady state. Loss of phospholipid asymmetry and externali-
zation of phosphatidylserine trigger the formation of MVs
[7, 9, 12, 13]. Not all MVs exhibit phosphatidylserine on the
surface, and their contents may vary depending on the cell
of origin as well as the stimulus triggering the formation of
MV [1]. The formation of MVs is depicted in Fig. 1: apoptosis
and cell activation cause a sudden release of calcium ions
by endoplasmic reticulum. The increased calcium ions flux
results from enzymatic imbalance caused by the inactivation
of the flippase, floppase and scramblase, leading to the loss
of lipid asymmetry in the cell membrane and exposure of
phosphatidylserine on the surface of the cell. The release of
calcium activates protein proteases e.g. calpain leading to the
proteolysis of cytoskeleton resulting in shedding of MVs from
the surface of the cell membrane [7, 9, 12, 13].
Microvesicles are formed in response to the activation
induced by various stimuli (thrombin, collagen, epinephrine,
diphosphoadenosine) and ex vivo during preparation and
storage of blood products for transfusion [14, 15]. Approx.
70–90% of circulating MVs originate from platelets [9, 16],
10–15% from endothelial cells [17], 4–8% from red blood cells
[18], and their formation is an essential stage of red bloodactivation or apoptosis through blebbling of cell membrane
1 mm
ds and proteins, can contain mRNA, miRNA
er layer contains phosphatidylserine, which in normal conditions is
lized in the cytoplasmic layer
cific surface antigens derived from the parent cell
elets, endothelial cells, erythrocytes, monocytes, lymphocytes, and
nulocytes
ends on the balance between release and removal from the
ulation
eased number in various pathological conditions
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Table I.
The role of microvesicles
Until recently the microvesicles were considered cell frag-
ments without any significant biological functions. Cur-
rently, it is believed that they exhibit a wide spectrum of
biological activity. The presence of the surface antigens and
various contents such as mRNAs, miRNAs, and proteins
suggests, that MVs are able to exert wide variety of
biological functions [20, 21]. Biological properties of MVs
largely depend on the cell of origin and the trigger that
stimulated their production [2, 10]. The first described
property of MVs was procoagulative activity, dependent
mainly on the presence of phosphatidylserine and tissue
factor on their surface. For this reason, MVs were initially
related to coagulation activation, atherosclerosis, cardio-
vascular disease or venous thrombosis.
The MVs are involved in hemostasis due to their pro-
and anticoagulative properties [4, 7, 8, 22]. As carriers of
bioactive molecules such as mRNA, miRNA and proteins
MVs play a key role in intercellular communication [20, 21],
mediate cell-to-cell signaling, regulate inflammatory pro-
cesses, vasospasm, fibrinolysis, and angiogenesis [23]. An
increased number of microvesicles was observed in patholo-
gical conditions, such as diabetes, cancer, autoimmune
disease, and sepsis [9, 14, 24, 25]. Increased number of
endothelial-derived microvesicles is observed in patients
with antiphospholipid syndrome, bleeding disorders and
hematological diseases. MVs can be released from mono-
cytes in response to various triggers, including proinflam-
matory cytokines. Neutrophil-derived microvesicles occur in
healthy individuals as well as various pathological conditions
[17]. MVs are involved in the response to hematopoietic stem
cell transplant, cancer progression, and apoptosis induction
[26]. Studies of microvesicles have contributed to the under-
standing of the mechanisms underlying the pathogenesis of
many diseases i.e. sickle cell disease, thrombotic thrombocy-
topenic purpura or paroxysmal nocturnal hemoglobinuria [4].
Increased release of MVs was observed during blood compo-
nents storage [27, 28], which suggests that they may be
responsible for some of the negative side effects observed
after blood transfusion [29, 30]. MVs derived from stored blood
components are able to modulate the activity of macro-
phages, neutrophils and T cells [29, 31, 32], and MV-activated
neutrophils might be directly involved in the pathogenesis of
TRALI [33]. Storage of blood components may also contribute
to the formation of MVs after transfusion [34].
Sample preparation
All preanalytical steps, regardless the method used, from
blood sampling to sample freezing, should be considered
a source of variation in MV analysis. To avoid the loss of
MVs and artifacts, strictly defined rules of blood sampling
and preparation of samples must be complied [35]. MVs can
be analyzed directly in the platelet-poor plasma obtained byserial centrifugation of citrate-treated blood or isolated from
the plasma by ultracentrifugation. Preferably, MVs analysis
should be performed in freshly prepared plasma to avoid
loss and damage of the MVs during freezing and thawing
[10, 36].
There are three key preanalytical factors influencing MVs
measurement:
(1) time to the first centrifugation of the sample;
(2) shaking the samples during transport;
(3) centrifugation parameters [20, 37].
In addition, the number and properties of MVs are
affected by such factors as:
(1) blood sampling method;
(2) the diameter of the needle;
(3) application of the tourniquet;
(4) anticoagulant used;
(5) the time between blood sampling and plasma isolation,
which is in part dependent on the anticoagulant used.
Preparation of the samples:
(1) Blood sampling:
- on an empty stomach, between 8 and 10 a.m.,
- from elbow flexure veins;
- use plastic tubes,
- use large diameter needle (19–21 G), to avoid hemolysis
in vitro, platelet activation, and MVs formation;
- without the use of the tourniquet; light turniquet can be
used only to locate the veins;
- use sodium citrate as an anticoagulant, because of its low
ability to activate the cells and generate artifacts in
comparison to EDTA and heparin (3.2%, 105–109 mM or
129 mM – 3.8%), ACD and CTAD may also be used (CTAD
inhibits the activation of platelets without affecting their
function). It is not recommended to use EDTA, heparin (as
it induces activation and aggregation of platelets in the
blood, does not chelate calcium ion chelates, does not
prevent the generation of MVs after sampling), and
hirudins.
- To avoid artifacts caused by vein damage during veni-
puncture, the first few ml after sampling (2–7.5 ml) should
be discarded [7, 10, 36–39].
Sample preparation procedure:
(1) Blood after sampling should be centrifuged as soon as
possible (preferably within 30 min to 1 h from sampling)
to isolate the plasma. The maximum time from sam-
pling to centrifugation is 2 h [7, 10, 36–39]. If necessary,
before processing blood samples should be stored at
room temperature, without mixing.
(2) Transport: the samples should be transported at room
temperature (20–25 8C), in the transport container in
vertical position. Rapid shaking and freezing during
transport are not permitted [37].
(3) Storage: due to the fact that, in most cases, samples
must be stored before analysis, fast freezing of the
samples in liquid nitrogen at 80 8C and further storage
at a temperature below 80 8C until analysis are recom-
mended. Such conditions protect the structure and func-
tion of the MVs. Maximum time for storage of the frozen
samples is 1 year. As far as possible, all of the samples
intended for the analysis of MVs should be stored for the
same period of time [10, 36].
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which reduces the formation of ice crystals [5, 10,
38–40].
(5) Centrifugation: the cells can be activated very easily
during the preparation of test samples, so the optimal
measurement of circulating MVs requires thorough
removal of platelets, red and white blood cells. Erythro-
cytes, platelets, and a large number of cell fragments are
effectively removed during centrifugation at 1200–
2000  g for 15–20 min [37–39, 41]. Depending on the
centrifugation speed, MVs might be lost in the pellet or
supernatant. There is also a risk of contamination of the
samples with the residual platelets, that forms during
freezing and thawing cycle and can lead to an artificial
increase in MVs number. To avoid generation of MVs ex
vivo two-step centrifugation should be performed. The
first centrifugation is intended to remove cells and
platelets (1500–10 000  g for 5–20 min). The second cen-
trifugation is intended to obtain MVs pellet (13 000–
100 000  g for 30–60 min). It is recommended to perform
two centrifugations for 15 min at 2500  g [39], followed
by another centrifugation at 13 000  g for 2 min to
obtain platelet-poor plasma. The largest number of MVs
can be obtained during centrifugation at 20 000  g for
20–30 min. Breaks should be avoided. After the centrifu-
gation steps plasma should be collected gently to avoid
the damage to the platelet layer [36–38, 41].
w?>In order to remove the residual platelets, filtration
using 0.8 mm filters might be performed, however, the
procedure may activate the platelets, induce MVs frag-
mentation, and in consequence lead to significant loss of
MVs [17].
Detection methods
Analysis of microvesicles includes four essential steps:
isolation, detection, typing and counting [10]. There are
many methods of MVs detection described in the literature,
aimed to determine their size, number, morphology, bio-
chemical composition, origin, physical characteristics, and
activity [42]. The individual methods differ in analytical and
pre-analytical confounding factors influencing the differences
in MVs measurement. The methods used for qualitative and
quantitative MVs analysis are technically challenging. One
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Laser scanning confocal microscopy (LSCM)Microvesicles can be analyzed using optical and non-
optical methods [42] (Table II).
I. Optical methods
1. Optical microscopy
In this method the sample is illuminated by visible
light, and the light scattered on the MVs is collected
through the lens of the microscope and focused on the
CCD camera (charge-coupled device). Optical microscopy
allows to measure the size and morphology of the MVs
larger than 200 nm. Quantification of microvesicles in the
specified volume is possible, but very time consuming.
This method does not provide any information on the
biochemical composition or cell of origin. The time
needed to analyze 10 000 MVs is a couple of hours.
Therefore, it is a time consuming and low-throughput
method [42]. Due to the small size of MVs and artifacts
formed due to Brownian motions, optical microscopy is
used in conjunction with image analysis software in NTA
method [44, 45].
2. Fluorescent microscopy
It is a type of optical microscopy optimized for the
detection of fluorescence. It detects surface proteins on
MVs using fluorescent-labeled probes. If auto fluorescence
is used, MVs size can be specified as a fluorescence signal
proportional to the size of the particles; however, if
fluorescent probes are used, the amplitude of the probe
fluorescence is not proportional to the size of the particles.
Therefore, this method does not allow to measure the size
of the MVs. Fluorescent microscopy enables quantitative
evaluation of the MVs with specific properties, on the
assumption that all MVs of a given type are stained. The
method is time consuming, low-throughput and the aver-
age measurement time is 1 h [42].
Highly Sensitive Fluorescent Microscopy (HSF) allows
detection of submicro- and nano-MVs. This technique
provides high detection sensitivity due to the high excita-
tion and quantum efficiency of fluorescence. Detection of
small MVs using HSF seems to be promising [46]. Fluores-
cence microscopy after FITC-labeled annexin V staining
allows the observation of formation and shedding of
microvesicles from the cell membrane [47]. Fluorescence
microscopy, due to constant advances in optical ima-
ging, is a promising technique for MVs characteristics;
however, its sensitivity in nano-MVs detection is limitedNon-optical methods
nsmission electron microscopy (TEM)
mic force microscopy (AFM)
edance-based flow cytometry
stern blotting (WB)
yme-linked immunosorbent assay (ELISA)
ctional assays
face plasmon resonance based imaging microscopy (SPRi)
face-assisted laser desorption/ionization mass spectrometry (SALDI-
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fluid [48].
3. Dynamic light scattering (DLS)
DLS is based on the analysis of the intensity of light
scattered by particles moving due to Brownian motions.
Brownian motions are random, disordered, continuous
movements of the particles in the fluid, caused by
collisions with particles of the solvent. Speed distribution
of the particles depends on the temperature and the
viscosity of the liquid and the diameter of the particles.
In general, the smaller the particles, the faster the
Brownian motions. If the beam falls on the surface of the
particle, the light is scattered in all directions, which is
measured by a detector positioned in an appropriate
distance. Brownian movements cause fluctuations in the
intensity of the scattered light. The rate of the changes in
the intensity of the scattered light depends on the size of
the particles and is used to calculate the size of the MVs.
The data is transformed using appropriate mathematical
algorithm and in consequence the information registered
by the detector regarding the changes in the intensity of
the scattered light is converted into the particle size
distribution graph (percentage of particles in relation to
their size). The result depends on the mathematical
algorithm applied. DLS allows to measure all particles at
the same time, shows the average size and detects
particles measuring from 1 nm to 6 mm. MVs size distri-
bution measured using DLS favors the presence of
a small number of large particles, which scatter the light
more efficiently than the small ones [38, 49]. In a few
minutes, this method is able to measure the relative and
absolute size distribution of MVs in a small sample
volume. The method is suitable for the determination of
the particle size in monodisperse samples. Detection in
polydisperse samples is less accurate and might be
affected by the presence of a small number of larger
particles, e.g. platelets or other pollutants. Two popula-
tions of particles can be analyzed at the same time only
when the diameter of the particles varies at least twofold.
DLS does not provide information on the biochemical
composition and the origin of MVs, and is targeted to
detect larger particles, therefore can ignore smaller
microvesicles [42, 49–51].
4. Flow cytometry
Flow cytometry is the most common method of
identification, quantification, and size assessment of the
MVs. In flow cytometry, MVs are detected in two stages:
based on the intensity of light scattering and using
fluorescently-labeled antibodies against specific surface
antigens. Flow cytometry allows simultaneous analysis of
morphology and subtype determination of thousands of
MVs per second. In this method, MVs cause scattering of
the laser light, which is measured by the detectors: one
detector positioned in line with the laser beam measures
the dispersion of the light (forward scatter, FSC), the
second detector, perpendicular to the laser beam mea-
sures the dispersion of the light (side scatter, SSC). FSC
indicates the size of the particle, while SSC provides
information about the internal complexity of the cell. The
intensity of the light scattering depends on the size ofthe particles, their shape, refractive index, and absorption.
The biochemical information is obtained by correlation
between FSC and SSC. Proper determination of structure
and size of MVs requires the use of fluorescently-labeled
calibration beads of known size. Identification of the size
of the MVs is done by comparing the intensity of light
scattering measured for MVs with intensity emitted by
the beads of known size. Total number of MVs can be
specified using commercially-available beads of known
concentration, that are added to a specific volume of the
sample [38, 41, 42, 50, 52]. Prior to flow cytometry
analysis, platelet-poor plasma or microvesicles suspen-
sion is labeled with fluorescent monoclonal antibodies
against specific surface antigens of the cell of origin.
These fluorescent probes are used to measure biochem-
ical and biological properties of the MVs as well as to
quantify and assess the subtype of the vesicles. In
addition, to confirm phospholipid properties of MVs,
annexin V or lactadhedrin can be used. Annexin V is
usually labeled with phycoerythrin (PE), and antibodies to
identify the origin of the MVs are labeled with fluorescein
isothiocyanide (FITC) [36, 53]. The main advantage of flow
cytometry is the double labeling to determine the origin
of the MVs. Using antibodies against several cellular
antigens, it is possible to characterize a large number of
antigens on a single MVs. One of the advantages of flow
cytometry is the possibility to analyze a large number of
samples in a short time [35]. However, it has some
limitations. Namely, it does not provide detailed informa-
tion on the morphology of the cells [42], does not detect
the full range of MVs, particles of smaller size are
detected with less effectiveness [54], and the obtained
results can vary even when analysis is performed using
identical systems [50]. Microvesicles measuring 0.1–
0.4 mm are too small to be detected by most of the
available flow cytometers and clusters of small MVs
might be counted as one event [42]. The results obtained
using flow cytometry depend on the type of device, its
settings, data analysis, as well as preparation and storage
of the sample, which may directly affect the level of MVs.
Although the use of antibodies against the surface
antigens usually allows you to specify the origin of the
MVs, under certain conditions, when the particles contain
a small amount of the antigen typically present in the
cell, the ability to bind the antibody is limited, specific
fluorescence is low, and in consequence MVs might not
be detected [35]. Flow cytometry does not require isola-
tion of MVs, which prevents loss and retains the morpho-
logical properties of the MVs [41].
5. Nanoparticle Tracking Analysis (NTA)
NTA is a method of direct detection and visualization
of particles in suspension, which allows you to specify
the size and the number of particles in the studied
sample. NTA enables you to specify the relative and
absolute size distribution of the particles in the sample.
In this method, the particles are illuminated by a laser
beam and light dispersion caused by Brownian motions
of these particles is analyzed by optical microscope. The
particle motion is tracked using a microscope coupled
with CCD camera. NTA relates the speed of movements
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particles, the size and the total number of MVs is
calculated by image analysis software [44, 45]. NTA
measures absolute particle size distribution in the range
from 50 nm to 1 mm and is accurate for particles larger
than 50 nm. Detection of smaller particles is not possible
due to microscope detection limit. There is a possibility
to obtain information on absolute particle size distribu-
tion, after calibration of the system using beads of known
number and size [42, 44]. NTA can detect particles smaller
than those detected by conventional flow cytometer, and
therefore it might be considered an alternative to flow
cytometer for quantification of MVs. Because the particles
are analyzed in suspension, there is no risk for morpho-
logical changes during fixation. NTA can be used to
analyze all MVs [44]. This method, however, has some
limitations. Although it can measure the particle in the
sample in details, the presence of large particles reduces
the number of small particles detected by the software.
NTA has a limited use for clinical samples, is slow and
time consuming. It does not provide any information on
the biochemical composition and the origin of MVs.
Moreover, it is not able to distinguish between cell-
derived MVs and other particles i.e. high-density lipopro-
teins [38, 51, 55].
6. Fluorescent NTA (F-NTA)
This method is similar to the NTA, but is based on the
fluorescence of the particles in the liquid. It measures an
absolute size distribution and the fluorescent signal of
the molecules in the liquid. F-NTA is a very sensitive
method, because fluorescence intensity is much higher
than the intensity of white light scattering. Fluorescent
particles are analyzed individually in real time. The
labeled particles are quantified and measured. The num-
ber of labeled particles is compared to the total number
of particles measured in light scatter mode [44]. F-NTA
seems to be adequate to fast measurement of size,
number, biochemical composition, and the origin of MVs.
It is specifically useful to identify the characteristics of
MVs directly in biological fluids [42]. F-NTA enables the
characterization of fluorescently-labeled MVs through
identification of their surface markers [49, 56, 57].
7. Raman spectroscopy
It is a spectroscopic method, based on the inelastic
scattering of monochrome, usually laser light, directly
using fluorescent probes or indirectly using mono- and
polyclonal antibodies [46, 56]. In this method the sample
is illuminated by monochromatic laser light. The vibra-
tions of the particles in the sample change the wave-
length of the scattered light, which is detected by
a specialized and sensitive spectrometer. The pattern of
vibration is specific to the molecule, what allows to
specify the biochemical composition of MVs without any
staining. Raman spectroscopy is a quantitative technique,
where signal strength is linearly proportional to the
number of particles. In microvesicles that fit in the size of
the probe, the intensity of the Raman signal is propor-
tional to the volume of a single vesicle. The method
allows to distinguish MVs from lipid particles of similar
size, or small platelets. It can specify the size, numberand composition of a single MV, without labeling. The
method is expensive, has limited availability and is very
time consuming (analysis of a single sample takes a few
hours) [42, 56]. The main advantage of this method is fast
and non-invasive analysis of the biochemical composi-
tion of MVs [46].
8. Stimulated emission depletion microscopy (STED)
STED is a type of fluorescent microscopy characterized
by high spatial resolution, allowing to specify the size of
the MVs. High resolution STED and fluorescent labeling of
microvesicles can potentially be used to obtain informa-
tion on the morphology and distribution of the labeled
receptors on the surface of larger microvesicles. This
method is very time consuming and requires several
hours to detect and characterize the MVs. The method is
still being developed [42, 58].
9. Laser scanning confocal microscopy (LSCM)
LSCM is a modern variation of fluorescent microscopy
using laser as the light source to increase the resolution
of the obtained images. In this method the individual
subtypes of MVs are identified on the basis of the
expression of specific antigens. MVs obtained by ultracen-
trifugation are labeled with antibodies conjugated with
fluorescein, and to prevent Brownian motions, the micro-
particles are fixed using annexin V. Similarly to other
optical methods, the results depend on the specificity and
affinity of the antibodies against the target antigen as well
as the density of the antigen on the surface of the MVs.
LCSM enables to obtain the morphological information i.e.
the size and the structure of the MVs. This method is time
consuming, requires several hours of analysis per sample
and is not suitable for direct determination of MVs in
plasma. LSCM allows direct visualization and evaluation of
the morphology of the MVs. One of the advantages is
detection in a small volume of sample [38, 48, 59].
II. Non-optical methods
1. Transmission electron microscopy (TEM)
TEM visualizes isolated MVs and allows you to specify
their structure [49]. Transmission electron microscope
uses electrons to obtain images. It is characterized by
much higher resolution, allowing to specify the size and
morphology of the MVs. TEM is not quantitative, but is
mainly used to assess the composition and morphology
of the MV membrane. It is not suitable for direct
detection of MVs in plasma, as it requires fixation and
dehydration of the sample, which has a direct impact on
the size and morphology of MVs. In this method, it is
necessary to increase the number of MVs in the sample
by ultracentrifugation, and in consequence the quantifi-
cation of MVs in the original sample is not possible. The
use of colloidal gold-labeled antibodies allows to obtain
the information on the antigen composition of the MVs.
This method requires time-consuming sample prepara-
tion and the measurement requires several hours [38, 42,
54, 60]. It provides information on the morphological
features of MVs, i.e. size, membrane structure, cytoskele-
ton [50, 61]. It is mainly used to visualize the MVs and
validate other measurements [38].
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scopy used to analyze MVs in temperatures below minus
100 8C. This method does not require staining and fixa-
tion of samples before analysis; however, the use of this
method to study the MVs requires further investigation
[46].
2. Atomic force microscopy (AFM)
AFM allows to detect a single MV and specify their
size in 3D [49]. Atomic force microscope is equipped with
a cantilever with a precise, ultra fine tip that is a few
mm long and less than 100 Ð in diameter, and is used to
scan the surface of the sample. In order to generate a
three-dimensional, high-resolution image, the microscope
scans the surface of the sample while the detector
equipped with laser measures the deflection of the canti-
lever moving along the sample. The measurement of the
deflection allows to generate a 3D image of the topography
of the surface. The strength of the interaction between the
tip and the sample depends on the distance between
them. The advantage of this method is the possibility to
detect the MVs directly in liquid, which allows to keep the
sample in a physiological state. To distinguish MVs from
the surface, this method requires strong binding of the
particles to a flat surface what may influence morphology
and hinder the determination of the correct diameter.
Mica, an insulating mineral, coated with antibodies, is
used to bind the MVs to the surface. This method requires
the isolation of the MVs from the plasma and concentra-
tion of the sample prior to the measurement, which
affects the morphology and the number of MVs. Fraction
of the isolated MVs is incubated to bind MVs to the surface
coated with antibodies [62]. The number of MVs on the
surface is calculated using an image processing software.
As the efficiency of binding to the surface of the MVs is
not known, the number of particles cannot be accurately
measured. AFM allows to detect small MVs and determine
the phenotype but cannot obtain information on func-
tional properties of MVs [38, 42, 49, 63, 64]. The measure-
ment requires several hours (about 2 h per sample), the
method is very labor-intensive [50, 64].
3. Impedance-based flow cytometry
It is a fast, non-optical method to identify, count, and
determine the size of the MVs. It uses the Coulter
principle to count and measure individual particles in
a liquid within a few seconds, by detecting changes in
electrical resistance produced by particles in suspension
[65]. It consists of two chambers separated by an insulat-
ing membrane containing a single channel. The chambers
are filled with electrolyte and an electrode is placed in
each of them. The particles introduced to the channel
induce reduction in electric current, which is measured
as a voltage pulse. The size of the impulse is proportional
to the size of the detected particles. MVs can be detected
directly in the platelet-poor plasma using fluorescent
antibodies. The lower detection limit is 300 nm, and in
consequence MVs less than 300 nm are detected less
efficiently. This method does not provide any information
on the morphology, biochemical composition or origin of
the particle, but can be combined with fluorescent flow
cytometry [42]. MVs size distribution can be assessedusing fluorescein-labeled antibodies, assuming that fluor-
escent signal amplitude is proportional to the volume or
surface of the particles. To measure the MVs, the system
is calibrated using fluorescent polystyrene beads of uni-
form size. The limit of detection depends on the diameter
of the flow chamber [38, 56, 65].
4. Western blotting (WB)
WB is a method that allows to specify the origin of
the MVs depending on the presence of various markers
[6]. Western blot analysis consists of five stages: electro-
phoretic separation of proteins, transfer of the proteins
to the nitrocellulose or polyvinylidene fluoride mem-
brane, labeling using primary antibodies against the
specific antigen, incubation with the secondary antibody
against the primary antibody, and finally, visualization
[57]. This method, however, requires the use of further
complementary methods such as NTA or electron micro-
scopy [46].
A large number of MVs to perform WB analysis, what
limits the applicability of this method for serum samples
[61, 66]. Moreover, WB allows to study specific subtypes
of MVs, but do not give any information about the size
and number of MVs [44].
5. Enzyme-linked immunosorbent assay (ELISA)
ELISA assay is a simple and reproducible method to
measure MVs. This method is based on the binding of
microvesicles by monoclonal antibodies conjugated with
fluorescein in the multiwell plate. Annexin V or antibo-
dies against surface antigens (so called catching antibo-
dies) are used to specifically bind plasma MVs, and
detection antibodies against surface antibodies are used
for the detection of the “cought” antibodies [67]. ELISA
allows quantitative analysis of MVs indirectly, using the
measurement of total amount of phosphorus or anionic
phospholipids. The advantages of MVs detection using
ELISA are: the possibility to examine a large number of
samples at the same time, no restrictions on size, wide
availability of the method, and quantitative assessment
of MVs. This method has also some disadvantages: it does
not analyze all types of MVs, detects soluble antigens, it
does not provide information about the size, and finally,
non-specific binding of annexin V limits its usability [7, 43,
50]. In this method, it is necessary to use fresh plasma,
because the freezing and thawing causes an increase in
the number of annexin-binding MVs [68]. ELISA allows you
to specify subtypes of MVs and is a high-throughput
method [38, 52].
6. Functional assays
Functional assays characterize microvesicles based on
their specific property. These methods are used for
indirect determination of the number of MVs based on
the measurement of the procoagulant or prothrombinase
activity. The main disadvantage of these methods is the
measurement of a single biological activity only. It is
impossible to analyze the size of the studied MVs [49, 50,
69–71]. The method is based on the measurement of
thrombin generation for indirect quantification of procoa-
gulant MVs. The measurement of the total number of
procoagulant MVs in plasma depends mainly on the
exposure of procoagulant phosphatidylserine on the sur-
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assay quantifies the level of circulating procoagulant MVs
coated with TF by measuring the formation of MVs-TF-
dependent factor Xa [72]. Functional assays have two
major limitations: they do not assess the size and number
of MVs in the sample. The advantage of the method is the
measurement of all MVs, regardless the size and origin. In
addition, the assays are easy to perform and allow to
analyze large number of samples. As of today, there are
limited and inconsistent data on the correlation between
the flow cytometry and functional assays in terms of MVs
analysis. The lack of a positive correlation is not surpris-
ing, considering the fact that highly sensitive method,
AFM, is able to detect 1000-times more MVs than flow
cytometry. Due to the fact that flow cytometry does not
allow to detect small MVs, it is understandable why the
results obtained in functional assays or using flow cyto-
metry are not correlated [64].
7. Surface plasmon resonance based imaging microscopy
(SPRi)
SPRi is a quantitative method allowing to assess the
size of the biological nanoparticles. It can be useful to
solve the majority of problems in MVs analysis [6]. SPRi
is a highly sensitive technique of biochemical analysis
that does not require any staining. Plasmon resonance,
the principle of the method, is associated with high
resolution diffraction generated on the surface a thin
metal surface [64]. SPRi equipment consists of an optical
part containing radiation source, transformer that converts
changes occurring on the surface of the metal to changes
of the refractive index and a system processing and
recording the data. SPRi apparatus is usually equipped
with a CCD camera to capture the reflected light. High
contrast signal between the cell edges and the surface
makes it easier to identify the edges and the cells. This
method do not allow to visualize the cells, however,
makes it possible to count them [73, 74]. Quantitative
interpretation of SPRi results can improve the analysis of
MVs and overcome the limitations of flow cytometry in
terms of low detectability of small MVs. Simultaneous use
of SPRi and fluorescent microscopy improves the sensitiv-
ity and selectivity of the method, which may improve
the identification of small MVs originating from different
cells that have been considered so far to be cell fragments
[46, 75, 76].
8. Surface-assisted laser desorption/ionization mass spec-
trometry (SALDI-MS)
SALDI-MS is a high-throughput technique capable to
detect the analytes of low molecular weight, including
MVs. The basic principle of MVs detection using SALDI-
MS is similar to mass spectrometry; however, SALDI-MS
uses organic matrix to prevent interference between the
sample and matrix molecules after application of laser
pulses [57]. The main advantage of this method is the
possibility to analyze MVs from various biological fluids
without special sample preparation. SALDI-MS measures
the size of the MVs with lower limit of detection approx.
10–30 nm what allow to study small microvesicles. How-
ever, the role of SALDi-MS in the detection of MVs
requires further investigation [6, 46].Identification of the origin of MVs
Lipid and protein composition of MVs is similar to the cell
of origin. Surface antigens allow to distinguish different
subpopulations of MVs and identify the origin of the vesicle
[3, 7, 77]. A list of antigens used to identify the subtype of
MVs is shown in Table III. Identification of the origins of
MVs isolated from plasma is possible using flow cytometry,
microscopy or WB. These methods provide detailed infor-
mation about the presence or absence of specific antigens in
small samples [61, 78]. Identification of the origin of MVs is
performed using fluorescently labeled monoclonal antibo-
dies against specific surface antigens. These antibodies can
distinguish MVs derived from platelets, white blood cells,
red blood cells, and endothelial cells [38]. The fluorescence
signal depends on the specificity and affinity of antibodies
to the target antigen and the number of antigens present on
the surface of the microvesicle. The correlation between the
fluorescence and the scattered light is used to identify
subtypes of MVs. Flow cytometry is the most commonly
used method for the determination of the origin of the MVs.
Fluorescence detectors in flow cytometry allow simulta-
neous detection of more than two antigens on a single MV.
Platelet-derived MVs are detected by a single staining using
antibodies against platelet antigens such as CD41 or CD42b,
or using a combination of anti-CD41/CD42b. In addition to
CD41 and CD42b, anti-CD31 antibody can be used for the
detection of platelet-derived MVs. CD41 and CD42b are
expressed on platelets only, while CD31 is present in large
amount on the endothelial cells and other cells such as
monocytes and granulocytes. The most common method of
endothelium-derived MVs staining is a combination of CD31
and anti-CD41 or anti-CD42b antibodies. Because CD31 is
a common marker of both platelets and endothelial cells,
platelet-derived MVs are CD31+/CD41+, while endothelium-
derived MVs are CD31+/CD41. The advantage of this
combination is high specificity. Other combinations can also
be used, such as: CD61 for platelet-derived MVs and CD144
for the endothelium-derived MVs. Detection of leukocyte-
derived MVs is difficult due to the variability of surface
markers in different populations. Leukocyte-derived MVs
can come from neutrophils, monocytes as well as B and
T cells. Leukocyte markers include CD11b/CD18, CD11a/
CD18, CD14, CD66, CD62L, or annexin [10, 35]. Anti-CD235a
antibodies are used to detect erythrocyte-derived-MVs [79].
Quantification of MVs
The total number of MVs can be specified using flow
cytometry, using commercial, fluorescently-labeled beads of
known concentration, that are added to the specific volume
of the sample. The number of MVs and beads together with
the volume of the sample are used to determine the total
number of MVs [10, 38, 41, 42, 50, 52]. Flow cytometry using
fluorescein-conjugated antibodies against surface antigens
and annexin V allow efficient counting of MVs in suspen-
sion [46]. Although not all MVs express phosphatidylserine
on the surface, annexin V staining enables to distinguish
Table III – Antigens used to identify specific MVs subsets according to cell of origin
MV subtype Antigen Alternative name
CD41 GPIIb




Eythrocyte-derived MVs CD235a Glycophorin A
Leukocyte-derived MVs CD45 Pan-lymphocyte antigen











a Shared antigen with other cell type.
a c t a h a e m a t o l o g i c a p o l o n i c a 4 8 ( 2 0 1 7 ) 3 1 6 – 3 2 9324MVs from large fragments of cell membrane and is widely
used to measure the total number of MVs. Staining of the
MVs with annexin V depends on the concentration of
calcium ions and the amount of phosphatidylserine in cell
membrane. Instead of annexin V it is possible to use
lactadherin, which is more sensitive to changes in the
expression of phosphatidylserine and detects the MVs in
the absence of calcium ions [80, 81]. Determination of the
number of MVs is also possible using AFM, NTA, and F-NTA.
These methods, including flow cytometry, are based on the
use of specific antibodies to the surface antigens of the MVs.
Quantification of MVs using F-NTA and AFM requires high
affinity antibodies. Quantification of MVs with these meth-
ods requires further development. Raman spectroscopy is
a quantitative technique, where signal strength is linearly
proportional to the number of particles. This method is very
time consuming, expensive, and its availability is limited
[42]. ELISA assay for the measurement of total phosphorus
or anionic phospholipids can be considered an alternative to
flow cytometry for quantification of MVs [43]. The quantifi-
cation of MVs requires correlation of the results with
standard curve.
Standardization of MVs research
The growing interest in the role of microparticles requires
standardization of methods used for their isolation and
analysis. Standardization is necessary to measure and
compare the number, origin and biological activity of MVs
in physiological and pathological conditions [82]. The meth-
ods used for isolation, qualitative and quantitative evalua-
tion of the MVs has not been standardized so far [6, 83].
Standardization is difficult because of small size and hetero-
geneity of microvesicles. Moreover, new methods for the
detection of even the smallest MVs in biological fluids are
constantly developed. These methods, employing modern
flow cytometry assays, provide information on the mechan-isms involved in the generation and biological functions of
MVs. In the past few years, a few attempts to standardize
cytometric methods for MVs studies have been made. It has
been shown, that to obtain consistent, reproducible results
of MVs measurement stable analytical conditions should be
maintained [79].
One of the attempts to standardize MVs measurement
was made by the International Society of Thrombosis and
Haemostasis (ISTH). In 2008, Robert, Poncelet and colleagues
described a reliable and reproducible method for measuring
platelet-derived MVs using Beckman Coulter Cytomics
FC500 flow cytometer. They used a mixture of fluorescent
beads of known size and showed that it is possible to count
the MVs reproducibly on different machines of the same
type. It was the first step toward the standardization of MVs
measurement methods [41]. In 2010, ISTH Scientific and
Standardization Subcommittees (SCC Vascular Biology, DIC
and Hemostasis & Malignancy) attempted to standardize the
flow cytometry method for the measurement of platelet-
derived MVs bigger than 0.5 mm. In this project, various
types of cytometers were calibrated using a set of synthetic,
sub-micron beads measuring 0.5 mm, 0.9 mm, and 3 mm. The
study involved 40 laboratories from 14 countries. Each of
them received a plasma sample with three different concen-
trations of MVs and studied it using the same batch of
antibodies for MVs staining. The results confirmed that
calibration strategy using beads is useful and the quantifica-
tion of MVs by flow cytometry is influenced not only by
analytical factors (i.e. laser, antibodies, device type, calibra-
tion of instruments), but also factors related to the prepara-
tion and storage of the sample. These studies have shown
that the standardization of platelet-derived MVs quantifica-
tion using flow cytometry is possible, but depends on both
the intrinsic characteristics of the flow cytometer as well as
calibration strategy. The calibration beads are useful stan-
dards that allow for the qualification of the device, but do
not constitute a universal standard in quantification of MVs.
The attempts to standardize quantification of MVs using
Table IV – The advantages and disadvantages of the methods used to detect MVs
Method Advantages Disadvantages
Optical microscopy - size assessment
- morphology assessment
- number of MVs
- time consuming
- low throughput
- it is not possible to measure the size and
morphology of MVs of less than 200 nm
Fluorescent microscopy - size assessment
- number of MVs
- time consuming
- low throughput
DLS - size assessment
- measurement of the relative and
absolute MVs size distribution
- fast
- it does not provide information on the
biochemical composition and cell origin
- less accurate in the polydispersion samples
- may exclude small MVs
Flow cytometry - allows analysis of a large number of
MVs in a short period of time
- number assessment
- determination of origin
- size assessment
- availability
- small sample volume
- analysis of different subtypes of MVs at
the same time
- possibility to use multiple markers for
the determination of the origin of the
MVs
- inaccurate for 100–400 nm particles
- small MVs may count as one
- does not provide detailed information on the
morphology of the cells
- determination of the origin of the MVs
depends on the specificity of the antibody
NTA and F-NTA - precise measurements
- assessment of the number of MVs
- determination of the absolute and the
relative distribution of MVs
- detection of small particles
- analysis of samples in suspension
- fast
- in combination with detection of




- requires clean-up of the sample from cell
debris and plasma proteins
Raman spectroscopy - size assessment
- assessment of the number of MVs










LSCM - determination of origin
- size assessment
- time consuming
- it is not suitable for the determination of MVs
in plasma
TEM - high resolution
- size assessment
- morphology assessment
- phenotype assessment using colloidal
gold labeling
- limited availability
- inability to determine the number of MVs
- requires dehydration and fixation of the
sample,
- not suitable for direct detection of MVs in
plasma
- time consuming
AFM - assessment of the number of MVs
- determination of origin
- accurate measuring with a three-
dimensional view of the MV structure,
- high resolution
- detection of single MVs
- detection in liquid allowing to keep the
sample in physiological condition
- limited availability
- determination of the origin of the MVs
requires using the surface coated with
antibodies
- requires isolation of the sample before the
analysis




Impedance-based flow cytometry - fast
- assessment of the number of MVs
- size assessment
- measurement directly in the plasma
- does not provide biochemical information
- MVs less than 300 nm are detected with
lower efficacy
WB - determination of origin
- semi-quantitative method
- inability to determine the number of MVs
- requires a large sample size
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Table IV (Continued )
Method Advantages Disadvantages
ELISA - determination of origin
- assessment of the number of MVs
- availability
- high throughput
- there are no limits to the size of the
measured particles
- measurement directly in the plasma
- inability to determine the number of MVs
- does not allow the analysis of all MVs
- detects soluble antigens
- require the use of fresh plasma
- does not give information on the size and
total number of MVs in plasma
- quantitative assessment based on the
presence of a single antigen
Functional assays - availability
- the assessment of biological activity
- determination of the relative number of
MVs
- easy to perform
- measurement of all MVs regardless of
the size and origin
- possible to study a large number of
samples
- inability to determine the size of MVs
- inability to determine the origin of MVs
- indirect quantification
- measures a signle biological activity
SPRI - quantitative assay
- size assessment
- no need tp stain the sample
- detects small MVs
- does not provide detailed information on the
morphology of the cells
- identification of small-sized MVs possible
while simultaneously using fluorescent
microscopy
SALDI-MS - high throughput
- allows to assess small size MVs
- the possibility to analyze MVs in
various biological fluids,
- no sample preparation
- determination of origin
- inability to determine the number of MVs
- requires improvement to be used in the
assessment of the MVs
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Biology ISTH launched a new initiative to standardize the
cytometric method, however, the results of this study have
not been announced yet [55]. The next step made by ISTH is
to standardize quantification of MVs smaller than 300 nm
[84].
To analyze MVs in clinical diagnostics it is necessary to
standardize not only device settings but also pre-analytical
conditions [79]. Despite significant progress in the analytical
phase, many pre-analytical variables may have a critical
impact on the determination of MVs, i.e. blood collection,
centrifugation conditions, the use of fresh/frozen samples
[37, 38]. Therefore, the main priority is to standardize pre-
analytical conditions. In 2015, in addition to attempts to
standardize the analytical conditions, ISTH attempted to
standardize pre-analytical conditions for the determination
of platelet-derived MVs [85]. Two pre-analytical protocols
have been used: any protocol used by the laboratory or
a specific protocol common for all laboratories. In the
common protocol, the blood was taken on an empty
stomach in the morning from 08:00 to 11:00, by venipunc-
ture at ulnar flexion with 21 gauge needle and light
tourniquet. The blood was drawn to a plastic tubes contain-
ing citrate (3.2%) at a minimum volume of 3.5 ml. The first
2–3 ml of blood were discarded and the samples were gently
mixed. The samples were transported in a transport con-
tainer, in a stable vertical position and stored at room
temperature (20–24 8C). Time to the first centrifugation was
maximum 2 h. The samples were spun down at 2500  g, at
room temperature, for 15 min. The plasma was collected
gently to a plastic tube leaving 1 cm, and then centrifugedfor a second time at 2500  g, at room temperature, for
15 min. The plasma was frozen in liquid nitrogen and stored
at 80 8C until analysis. The use of this protocol allowed to
reduce interlaboratory variability, however, it still remained
too high to implement the method into routine clinical
practice. Low reproducibility of the results is observed even
in cases when a specific pre-analytical protocol is strictly
implemented, what suggests that there are other, unidenti-
fied parameters influencing the number of MVs. Moreover,
there is a need to standardize specific pre-analytical condi-
tions for various subpopulations of MVs, including erythro-
cyte-, leukocyte- and endothelium-derived MVs [82, 85].
In the last 5 years, 2 methods of reproducible determina-
tion of platelet-derived MVs in plasma samples were pre-
sented. Both methods are based on flow cytometry with
reference beads of various sizes. Both systems provide
reproducible method for the analysis of platelet-derived
MVs. However, these methods work only on certain cyt-
ometers, which is incompatible with the requirements of
standardization [84].
Conclusions
Various methods are used to analyze MVs, and each of
them has some pros and cons – see Table IV. These
methods are often difficult to access, low-throughput or do
not provide both qualitative and quantitative data. The
exact measurement of the MVs is difficult due to the lack of
standardized testing methods. The results of MVs measure-
ments vary between different laboratories, not only because
a c t a h a e m a t o l o g i c a p o l o n i c a 4 8 ( 2 0 1 7 ) 3 1 6 – 3 2 9 327of the discrepancies in the pre-analytical steps, but also in
the analytical methods used to measure the MVs [10].
Review of the literature clearly indicates the need for further
development of the MVs studies. Measuring the MVs in
reproducible way is still a challenge. Characterization of
MVs remains difficult due to the small size and diversity of
the particles in terms of their phospholipid content and
antigen profile. In addition, there is still no agreement
regarding the best markers to define subpopulations of MVs
derived from vascular endothelium, leukocytes or tumor,
which has the highest predictive value [8]. Considering all
the methods mentioned above, flow cytometry seems to be
the best technique to study MVs because of the possibility
of multiparametric analysis. It provides not only quantita-
tive, but also qualitative information, thereby it allows to
identify the origin of cell-derived MVs and despite many
limitations it still remains the most commonly used techni-
que for the detection and analysis of the MVs [50]. Micro-
scopic methods, ELISA, and functional tests are routinely
used, although they do not offer the same high-quality
information as flow cytometry. Measurement of MVs can be
crucial in the diagnosis and therapy of many diseases, and
the ability to compare the obtained data is a necessary to
explore the full potential of the MVs. However, standardiza-
tion of methods used to analyze MVs is required to imple-
ment MVs assessment into clinical practice.
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